

Advanced Cell Technology (ACTC.OB): ACT is a regenerative medicine company specializing in patient-specific therapies. The company's Myoblast program is an autologous (from the patient's own body) adult stem cell therapy for the treatment of heart disease. The Myoblast program has successfully completed four Phase I clinical trials and has clearance from the FDA to begin Phase II trials.

The company is also pursuing a treatment for RPE (retinal pigment epithelial). Another target area involves stem cell treatments for retinal degenerative disorders. The company has completed a collaboration with the Casey Eye Institute at Oregon Health and Science University in the area retinal degenerative disorders and expects new therapies for treating indications such as age-related macular degeneration to come from this work.

In 2006 ACT announced a novel technique to generate embryonic stem cell lines without destroying embryos, a breakthrough in the ethical debate surrounding the industry. Since then, the company has announced on multiple occasions the creation of human embryonic stem cell lines without destroying the developmental potential of the embryos.